Kiniksa Pharmaceuticals Ownership
| KNSA Stock | USD 18.54 0.15 0.82% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 71 M | Current Value 71.7 M | Avarage Shares Outstanding 58.3 M | Quarterly Volatility 15.2 M |
Kiniksa |
Kiniksa Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The book value of Kiniksa Pharmaceuticals was now reported as 6.06. The company has Price/Earnings To Growth (PEG) ratio of 0.25. Kiniksa Pharmaceuticals recorded a loss per share of 0.12. The entity had not issued any dividends in recent years. The firm had 1:1 split on the 28th of June 2024. Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals is traded on NASDAQ Exchange in the United States. To find out more about Kiniksa Pharmaceuticals contact Sanj Patel at 781 431 9100 or learn more at https://www.kiniksa.com.Kiniksa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Kiniksa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kiniksa Pharmaceuticals backward and forwards among themselves. Kiniksa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Kiniksa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-09-30 | 741.3 K | Driehaus Capital Management Llc | 2024-09-30 | 730.9 K | State Street Corp | 2024-09-30 | 704.7 K | Fmr Inc | 2024-09-30 | 696.8 K | Rice Hall James & Associates, Llc | 2024-09-30 | 649.6 K | Tang Capital Management Llc | 2024-09-30 | 628.6 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 531.3 K | Millennium Management Llc | 2024-09-30 | 516.5 K | Goldman Sachs Group Inc | 2024-09-30 | 508.4 K | Blackrock Inc | 2024-09-30 | 3.8 M | Vanguard Group Inc | 2024-09-30 | 3.3 M |
Kiniksa Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kiniksa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kiniksa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kiniksa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kiniksa Pharmaceuticals Outstanding Bonds
Kiniksa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Kiniksa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Kiniksa bonds can be classified according to their maturity, which is the date when Kiniksa Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Kiniksa Pharmaceuticals Corporate Filings
F4 | 15th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 21st of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.674 | Return On Assets |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.